Company intelligence / Profile preview

Amicoat

Sandvika / Oslo / Tromsø*, Akershus / Troms og Finnmark / Oslo region*, Norwayamicoat.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Amicoat has developed a patented antimicrobial peptide technology that rapidly kills bacteria by disrupting their cell membranes. Their lead product AMC‑109 demonstrates rapid bactericidal activity with minimal risk of resistance development. The company focuses on licensing this technology to manufacturers of medical devices and other products to reduce infection risk. Efficacy has been demonstrated against bacteria, some viruses, and fungi. The business model centers around milestone payments and license income from partners using their technology.

Therapeutic areas: Infectious Diseases
Modalities: Antimicrobial peptides (synthetic and nature-inspired)
Industry: Chemicals & Materials

Drug pipeline

1 asset

AMC-109

Pre-clinical

Indications: Bacterial infections, Viral infections, Fungal infections

Partnerships

Multiple undisclosed partners manufacturing finished products using Amicoat’s technology.

Beyond the preview

Go deeper on Amicoat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amicoat.

Explore the full profile